Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on. The US Food and Drug Administration (FDA) ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand access soon.

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy. Then it smashed into roadblocks - shortages that led Novo to limit demand by ...

(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Despite their widely touted benefits — primarily weight loss and diabetes control, among others — GLP-1 medications have also ...

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...